A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to ...

The patent on weight loss injection semaglutide is due to expire in 2031, which will let other companies make cut-price ...

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

Amble Health's website states it is a platform connecting patients to licensed healthcare professionals online, who can ...

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending ...

Cigna’s pharmacy benefits unit Evernorth said the deal will bring prices down for employers and their workers.

After the the FDA declared an end to the shortage of GLP-1 medications, compounded versions of the drug must be out of the market by Thursday.

Holy Moley Rocky! Pipsqueak pharmacy wins slam dunk verdict against Big Pharma—re: Ozempic and Wegovy?! Incredible story with ...